ClinicalTrials.gg
CompletedNCT02686658Updated Jun 10, 2025Results posted

Zimura in Participants With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

A Phase 2/3 interventional study of Avacincaptad Pegol and Sham in Geographic Atrophy and Dry Age-Related Macular Degeneration, sponsored by IVERIC bio, Inc.. Completed at 78 sites in 7 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2025-06-10.

Sponsored by IVERIC bio, Inc. (part of Astellas Pharma Inc) · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
286
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 131 studies in Geographic Atrophy with a site in United States — 35 open to participants now, 45 under way, 5 of them phase 3. Geographic Atrophy · United States.

Enrollment
27th of 107
286 · median 98
Started
2015
with 5 others
Phase 2/3
5 of 131
1 open now
Registered
45th of 131
by date

Among the 131 studies in Geographic Atrophy with a site in United States, this one is the 27th largest by enrollment of the 107 interventional ones that give a count, is one of 6 that started in 2015, is one of 5 in phase 2/3, and was the 45th registered.

Geographic Atrophy

188 studies on the registry are indexed under Geographic Atrophy; 52 are open to participants now.

Browse Geographic Atrophy studies →

Open to participants now

35 of the 131 studies in Geographic Atrophy with a site in United States are open now. Recruiting first, the newest first:

30 more — sign in →

All 35 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 40 Geographic Atrophy studies recruiting now, 31 (78%) set no upper age limit and none (0%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 131 studies in Geographic Atrophy with a site in United States, or all of them as a file.
02

Study summary

The objectives of this study were to evaluate the safety and efficacy of Zimura intravitreal (IVT) administration when administered in participants with geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD).

Read the detailed description

Participants will receive monthly intravitreal injections of Zimura or Sham for 18 months.

03

Conditions studied

  • Geographic Atrophy
  • Dry Age-Related Macular Degeneration

Browse trials for

Keywords

  • Geographic Atrophy (GA)
  • Dry age-related macular degeneration
  • AMD
  • Zimura (previous name)
  • Anti-inflammatory
  • complement factor C5 inhibitor
  • ARC1905
  • avacincaptad pegol
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants of either gender aged ≥ 50 years
  • Diagnosis of Non-foveal GA secondary to dry AMD

Exclusion criteria

Exclusion Criteria:

  • Evidence of Choroidal Neovascularization (CNV)
  • GA secondary to any condition other than AMD
  • Any prior treatment for AMD or any prior intravitreal treatment for any indication in either eye, except oral supplements of vitamins and minerals
  • Any intraocular surgery or thermal laser within three (3) months of trial entry
  • Any prior thermal laser in the macular region, regardless of indication
  • Any ocular or periocular infection in the twelve (12) weeks
  • Previous therapeutic radiation in the region of the study eye
  • Any sign of diabetic retinopathy in either eye
05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
286 participants (actual)

Study arms

  • Experimental
    Avacincaptad Pegol 1 mg [Part 1]

    Participants received 1 mg of Avacincaptad Pegol in the study eye administered via IVT injection (50 µL) on Day 1 and monthly up to 18 months.

    Drug: Avacincaptad Pegol

  • Experimental
    Avacincaptad Pegol 2 mg [Part 1]

    Participants received 2 mg of Avacincaptad Pegol in the study eye administered via IVT injection (100 µL) on Day 1 and monthly up to 18 months.

    Drug: Avacincaptad Pegol

  • Sham comparator
    Sham [Part 1]

    Participants received a Sham injection of an empty, needleless syringe administered in the study eye on Day 1 and monthly up to 18 months.

    Other: Sham

  • Experimental
    Avacincaptad Pegol 2 mg (Avacincaptad Pegol 2mg+Sham) [Part 2]

    Participants received 2 mg of Avacincaptad Pegol in the study eye administered via IVT injection (100 µL) and a subsequent Sham administration on Day 1 and monthly up to 18 months.

    Drug: Avacincaptad Pegol · Other: Sham

  • Experimental
    Avacincaptad Pegol 4 mg (Avacincaptad Pegol 2mg+Avacincaptad Pegol 2mg) [Part 2]

    Participants received 4 mg of Avacincaptad Pegol in the study eye administered via two consecutive IVT injections (2 x 100 µL) on Day 1 and monthly up to 18 months.

    Drug: Avacincaptad Pegol

  • Sham comparator
    Sham (Sham+Sham) [Part 2]

    Participants received two consecutive Sham injections of empty, needleless syringes administered in the study eye on Day 1 and monthly up to 18 months.

    Other: Sham

Interventions

  • Avacincaptad Pegol 20 mg/mL solution for intravitreal (IVT) injection

    Also known as: Zimura (previous name), IZERVAY, ARC1905

  • OtherSham

    The Sham procedure included the blunt opening of an empty, needleless syringe barrel placed on the conjunctiva in the inferotemporal quadrant of the eyeball to simulate the pressure of an injection.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Geographic Atrophy as Measured by Fundus Autofluorescence

    The least squares mean change in geographic atrophy (GA) from baseline to Month 12 was measured by fundus autofluorescence (FAF). The square root of the GA area was used in the analysis. Per statistical analysis plan, only the Zimura 2 mg and 4 mg groups were evaluated for this primary endpoint; the Zimura 1 mg group was for descriptive purposes only.

    Time frame: Baseline and 12 months

Secondary outcomes

  1. Change From Baseline in Best Corrected Visual Acuity Using Early Treatment Diabetic Retinopathy Study Letters

    The least squares mean change in best-corrected visual acuity (BCVA) from baseline to Month 12 was measured using early treatment diabetic retinopathy study \[ETDRS\] letters. Per statistical analysis plan, only the Zimura 2 mg and 4 mg groups were evaluated for the secondary endpoints; the Zimura 1 mg group was for descriptive purposes only.

    Time frame: Baseline and 12 months

  2. Change From Baseline in Low Luminance BCVA Using Early Treatment Diabetic Retinopathy Study Letters

    The least squares mean change in low luminance (LL) BCVA from baseline to Month 12 was measured using ETDRS letters. Per statistical analysis plan, only the Zimura 2 mg and 4 mg groups were evaluated for the secondary endpoints; the Zimura 1 mg group was for descriptive purposes only.

    Time frame: Baseline and 12 months

07

Results

Posted May 11, 2023

Participant flow

Participant flow — Overall Study
MilestoneZimura 1 mg [Part 1]Zimura 2 mg [Part 1]Sham [Part 1]Zimura 2 mg (Zimura 2mg+Sham) [Part 2]Zimura 4 mg (Zimura 2mg+Zimura 2mg) [Part 2]Sham (Sham+Sham) [Part 2]
Started262526428384
Month 12231919345672
Completed221817304668
Not completed479123716
Withdrew: Adverse event001121
Withdrew: Investigator decision000121
Withdrew: Sponsor decision1215132
Withdrew: Lost to follow-up002001
Withdrew: Death100111
Withdrew: Withdrawal by subject2544178
Withdrew: Placed in hospice care001000
Withdrew: Participant non-compliance000001
Withdrew: Concern over coronavirus disease care000021

Outcome measures

PrimaryChange From Baseline in Geographic Atrophy as Measured by Fundus Autofluorescence

The least squares mean change in geographic atrophy (GA) from baseline to Month 12 was measured by fundus autofluorescence (FAF). The square root of the GA area was used in the analysis. Per statistical analysis plan, only the Zimura 2 mg and 4 mg groups were evaluated for this primary endpoint; the Zimura 1 mg group was for descriptive purposes only.

Time frame:
Baseline and 12 months
Reported as:
Least squares mean · millimeters (mm)
Change From Baseline in Geographic Atrophy as Measured by Fundus Autofluorescence
millimeters (mm)Zimura 2 mg [Part 1 & Part 2 Combined]Sham [Part 1 & Part 2 Combined]Zimura 4 mg [Part 2]Sham [Part 2]
Change From Baseline in Geographic Atrophy as Measured by Fundus Autofluorescence0.292 ± 0.0770.402 ± 0.0750.321 ± 0.0740.444 ± 0.072
Statistical analysis
  • Zimura 2 mg [Part 1 & Part 2 Combined] vs Sham [Part 1 & Part 2 Combined] · Model for repeated measures (MRM) · p = 0.0072 · Least squares mean difference: 0.110
  • Zimura 4 mg [Part 2] vs Sham [Part 2] · Model for repeated measures (MRM) · p = 0.0051 · Least squares mean difference: 0.124
SecondaryChange From Baseline in Best Corrected Visual Acuity Using Early Treatment Diabetic Retinopathy Study Letters

The least squares mean change in best-corrected visual acuity (BCVA) from baseline to Month 12 was measured using early treatment diabetic retinopathy study \[ETDRS\] letters. Per statistical analysis plan, only the Zimura 2 mg and 4 mg groups were evaluated for the secondary endpoints; the Zimura 1 mg group was for descriptive purposes only.

Time frame:
Baseline and 12 months
Reported as:
Least squares mean · ETDRS Letters
Change From Baseline in Best Corrected Visual Acuity Using Early Treatment Diabetic Retinopathy Study Letters
ETDRS LettersZimura 2 mg [Part 1 & Part 2 Combined]Sham [Part 1 & Part 2 Combined]Zimura 4 mg [Part 2]Sham [Part 2]
Change From Baseline in Best Corrected Visual Acuity Using Early Treatment Diabetic Retinopathy Study Letters-7.90 ± 2.66-9.29 ± 2.59-3.79 ± 3.11-3.51 ± 2.99
Statistical analysis
  • Zimura 2 mg [Part 1 & Part 2 Combined] vs Sham [Part 1 & Part 2 Combined] · Model for repeated measures (MRM) · p = 0.3464 · Least squares mean difference: 1.39
  • Zimura 4 mg [Part 2] vs Sham [Part 2] · Model for repeated measures (MRM) · p = 0.8830 · Least squares mean difference: -0.28
SecondaryChange From Baseline in Low Luminance BCVA Using Early Treatment Diabetic Retinopathy Study Letters

The least squares mean change in low luminance (LL) BCVA from baseline to Month 12 was measured using ETDRS letters. Per statistical analysis plan, only the Zimura 2 mg and 4 mg groups were evaluated for the secondary endpoints; the Zimura 1 mg group was for descriptive purposes only.

Time frame:
Baseline and 12 months
Reported as:
Least squares mean · ETDRS Letters
Change From Baseline in Low Luminance BCVA Using Early Treatment Diabetic Retinopathy Study Letters
ETDRS LettersZimura 2 mg [Part 1 & Part 2 Combined]Sham [Part 1 & Part 2 Combined]Zimura 4 mg [Part 2]Sham [Part 2]
Change From Baseline in Low Luminance BCVA Using Early Treatment Diabetic Retinopathy Study Letters-1.03 ± 3.40-1.41 ± 3.301.53 ± 3.532.97 ± 3.39
Statistical analysis
  • Zimura 2 mg [Part 1 & Part 2 Combined] vs Sham [Part 1 & Part 2 Combined] · Model for repeated measures (MRM) · p = 0.8405 · Least squares mean difference: 0.38
  • Zimura 4 mg [Part 2] vs Sham [Part 2] · Model for repeated measures (MRM) · p = 0.5017 · Least squares mean difference: -1.44

Adverse events

Collected over Adverse events were recorded starting at Day 1 after the first dose of study drug and continuing until 30 days after the last dose or until the last follow-up visit required by the protocol, whichever comes later (up to approximately 18 months from first dose).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Zimura 1 mg [Part 1]1/26 (3.8%)3/26 (11.5%)13/26 (50%)
Zimura 2 mg [Part 1]0/25 (0%)4/25 (16%)13/25 (52%)
Sham [Part 1]0/26 (0%)7/26 (26.9%)10/26 (38.5%)
Zimura 2 mg (Zimura 2mg+Sham) [Part 2]1/42 (2.4%)8/42 (19%)34/42 (81%)
Zimura 4 mg (Zimura 2mg+Zimura 2mg) [Part 2]1/83 (1.2%)21/83 (25.3%)66/83 (79.5%)
Sham (Sham+Sham) [Part 2]1/84 (1.2%)21/84 (25%)49/84 (58.3%)
Zimura (Any Dose) [Part 1 & Part 2 Combined]3/176 (1.7%)36/176 (20.5%)126/176 (71.6%)
Sham [Part 1 & Part 2 Combined]1/110 (0.9%)28/110 (25.5%)59/110 (53.6%)
Most frequent serious events
Showing 10 of 72
Most frequent serious events
EventZimura 1 mg [Part 1]Zimura 2 mg [Part 1]Sham [Part 1]Zimura 2 mg (Zimura 2mg+Sham) [Part 2]Zimura 4 mg (Zimura 2mg+Zimura 2mg) [Part 2]Sham (Sham+Sham) [Part 2]Zimura (Any Dose) [Part 1 & Part 2 Combined]Sham [Part 1 & Part 2 Combined]
Upper gastrointestinal haemorrhageGastrointestinal disorders0/261/250/260/420/830/841/1760/110
CholelithiasisHepatobiliary disorders0/261/250/260/420/830/841/1760/110
CellulitisInfections and infestations0/261/250/261/420/830/842/1760/110
Femur fractureInjury, poisoning and procedural complications0/261/251/260/421/830/842/1761/110
Ulna fractureInjury, poisoning and procedural complications0/261/250/260/420/830/841/1760/110
Cerebrovascular accidentNervous system disorders1/261/250/260/421/831/843/1761/110
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/261/250/260/421/833/842/1763/110
Ventricular extrasystolesCardiac disorders1/260/250/260/420/830/841/1760/110
Coronary artery diseaseCardiac disorders0/260/251/260/420/832/840/1763/110
Lower gastrointestinal haemorrhageGastrointestinal disorders1/260/250/260/420/830/841/1760/110
Most frequent other events
Showing 10 of 27
Most frequent other events
EventZimura 1 mg [Part 1]Zimura 2 mg [Part 1]Sham [Part 1]Zimura 2 mg (Zimura 2mg+Sham) [Part 2]Zimura 4 mg (Zimura 2mg+Zimura 2mg) [Part 2]Sham (Sham+Sham) [Part 2]Zimura (Any Dose) [Part 1 & Part 2 Combined]Sham [Part 1 & Part 2 Combined]
Conjunctival haemorrhage *Eye disorders2/262/251/269/4228/8312/8441/17613/110
Intraocular pressure increasedInvestigations1/262/250/264/4219/831/8426/1761/110
FallInjury, poisoning and procedural complications0/260/250/268/426/837/8414/1767/110
Neovascular age-related macular degeneration*Eye disorders3/262/252/267/4211/832/8423/1764/110
Urinary tract infectionInfections and infestations2/260/252/267/4210/838/8419/17610/110
NasopharyngitisInfections and infestations1/263/250/264/423/835/8411/1765/110
Vitreous detachment*Eye disorders3/260/250/262/424/836/849/1766/110
Conjunctival hyperaemia*Eye disorders0/260/250/263/429/834/8412/1764/110
Eye pain*Eye disorders0/261/250/261/428/833/8410/1763/110
Punctate keratitis*Eye disorders0/260/250/264/426/838/8410/1768/110

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Zimura 1 mg [Part 1]Zimura 2 mg [Part 1]Sham [Part 1]Zimura 2 mg (Zimura 2mg+Sham) [Part 2]Zimura 4 mg (Zimura 2mg+Zimura 2mg) [Part 2]Sham (Sham+Sham) [Part 2]Total
<=18 years0000000
Between 18 and 65 years34265424
>=65 years232124367880262
Sex: Female, Male
Sex: Female, Male(Participants)Zimura 1 mg [Part 1]Zimura 2 mg [Part 1]Sham [Part 1]Zimura 2 mg (Zimura 2mg+Sham) [Part 2]Zimura 4 mg (Zimura 2mg+Zimura 2mg) [Part 2]Sham (Sham+Sham) [Part 2]Total
Female151818275861197
Male117815252389
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Zimura 1 mg [Part 1]Zimura 2 mg [Part 1]Sham [Part 1]Zimura 2 mg (Zimura 2mg+Sham) [Part 2]Zimura 4 mg (Zimura 2mg+Zimura 2mg) [Part 2]Sham (Sham+Sham) [Part 2]Total
Hispanic or Latino1110115
Not Hispanic or Latino252425428283281
Unknown or Not Reported0000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Zimura 1 mg [Part 1]Zimura 2 mg [Part 1]Sham [Part 1]Zimura 2 mg (Zimura 2mg+Sham) [Part 2]Zimura 4 mg (Zimura 2mg+Zimura 2mg) [Part 2]Sham (Sham+Sham) [Part 2]Total
American Indian or Alaska Native0000000
Asian1000001
Native Hawaiian or Other Pacific Islander0000000
Black or African American0000011
White252525428282281
More than one race0000000
Unknown or Not Reported0010113
08

Study locations

78 sites
  • Phoenix, Arizona 85053, United States
  • Tucson, Arizona 85704, United States
  • Tucson, Arizona 85710, United States
  • Campbell, California 95008, United States
  • Fresno, California 93720, United States
  • Fullerton, California 92835, United States
  • La Jolla, California 92093, United States
  • Mountain View, California 94040, United States
  • Redlands, California 92374, United States
  • Sacramento, California 95819, United States
  • Sacramento, California 95841, United States
  • Santa Ana, California 92705, United States
  • Denver, Colorado 80210, United States
  • Altamonte Springs, Florida 32701, United States
  • Boynton Beach, Florida 33426, United States
  • Melbourne, Florida 32901, United States
  • Saint Petersburg, Florida 33711, United States
  • Stuart, Florida 34994, United States
  • Winter Haven, Florida 33880, United States
  • Augusta, Georgia 30909, United States
  • Marietta, Georgia 30060, United States
  • Retina Consultants of Hawaii
    'Aiea, Hawaii 96701, United States
  • West Des Moines, Iowa 50266, United States
  • Shawnee Mission, Kansas 66204, United States
  • Wichita, Kansas 67214, United States
  • Baltimore, Maryland 21209, United States
  • Chevy Chase, Maryland 20815, United States
  • Boston, Massachusetts 02114, United States
  • Springfield, Massachusetts 01107, United States
  • Grand Rapids, Michigan 49546, United States
  • Henderson, Nevada 89052, United States
  • Reno, Nevada 89502, United States
  • Rochester, New York 14620, United States
  • Syracuse, New York 13224, United States
  • Asheville, North Carolina 28803, United States
  • Charlotte, North Carolina 28210, United States
  • Hickory, North Carolina 28602, United States
  • Cincinnati, Ohio 45242, United States
  • Cleveland, Ohio 44130, United States
  • Cleveland, Ohio 44136, United States
  • Portland, Oregon 97221, United States
  • Philadelphia, Pennsylvania 19107, United States
  • West Mifflin, Pennsylvania 15122, United States
  • Ladson, South Carolina 29456, United States
  • West Columbia, South Carolina 29169, United States
  • Abilene, Texas 79606, United States
  • Amarillo, Texas 79106, United States
  • Austin, Texas 78705, United States
  • Grapevine, Texas 76051, United States
  • Houston, Texas 77030, United States
  • The Woodlands, Texas 77384, United States
  • Willow Park, Texas 76087, United States
  • Salt Lake City, Utah 84107, United States
  • Salt Lake City, Utah 84132, United States
  • Richmond, Virginia 23235, United States
  • Clinical hospital center Osijek
    Osijek, 31000, Croatia
  • Fakultni Nemocnice Brno
    Brno, 62500, Czechia
  • Faculty Hospital Hradec Kralove
    Hradec Králové, 50005, Czechia
  • Fakultni nemocnice Olomouc
    Olomouc, 77900, Czechia
  • Axon Clinical SRO
    Praha, 15000, Czechia
  • East Tallinn Central Hospital
    Tallinn, 10138, Estonia
  • Dr.Kai Noor Eye Clinic
    Tallinn, 11412, Estonia
  • Peterfy Korhaz-Rendelointezet Orszagos Traumatologiai Intezet
    Budapest, 1076, Hungary
  • Budapest, 1083, Hungary
  • Budapest, 1106, Hungary
  • Budapest, 1133, Hungary
  • Budapest, 1145, Hungary
  • Debrecen, 4012, Hungary
  • Pecs, 7621, Hungary
  • Szeged, 6720, Hungary
  • Veszprém, 8200, Hungary
  • Rambam Medical Center
    Haifa, 3109601, Israel
  • Hadassah University Hospital
    Jerusalem, 91120, Israel
  • Meir Medical Center
    Kfar Saba, 4428164, Israel
  • Rabin Medical Center
    Petah tikva, 4941492, Israel
  • Kaplan Medical Center
    Reẖovot, 76100, Israel
  • Tel-Aviv Sourasky Medical Center
    Tel Aviv, 6423906, Israel
  • Pauls Stradins Clinical University Hospital
    Riga, LV1002, Latvia
09

References and documents

Publications

  • Jaffe GJ, Westby K, Csaky KG, Mones J, Pearlman JA, Patel SS, Joondeph BC, Randolph J, Masonson H, Rezaei KA. C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial. Ophthalmology. 2021 Apr;128(4):576-586. doi: 10.1016/j.ophtha.2020.08.027. Epub 2020 Sep 1. PubMed 32882310 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2015 to primary completion in Sep 2019, 45 months.

Results were first posted in May 2023, 3 years 7 months after primary completion. A results delay was requested in Sep 2020.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2016
First posted
Feb 19, 2016
StartActual
Dec 15, 2015
Primary completionActual
Sep 26, 2019
CompletionActual
Apr 23, 2020
Results delay requested
Sep 30, 2020
Results first posted
May 11, 2023
Last update
Jun 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02686658
Lead sponsor
IVERIC bio, Inc.
Responsible party
Sponsor
First posted
Feb 19, 2016
Start date
Dec 15, 2015
Primary completion
Sep 26, 2019
Completion
Apr 23, 2020
Results posted
May 11, 2023
Last update
Jun 10, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Avacincaptad pegol

Start the discussion